Willie Earley1, Suresh Durgam2, Kaifeng Lu2, Adam Ruth3, György Németh4, István Laszlovszky4, Lakshmi N Yatham5. 1. Allergan, Harborside Financial Center, Plaza V, Jersey City, NJ, 07311 USA. Electronic address: Willie.Earley@Allergan.com. 2. Allergan, Harborside Financial Center, Plaza V, Jersey City, NJ, 07311 USA. 3. Prescott Medical Communications Group, Chicago, IL, USA. 4. Gedeon Richter Plc, Budapest, Hungary. 5. University of British Columbia, Vancouver, BC, Canada.
Abstract
BACKGROUND:Rates of response and remission are measures that endorse the clinical significance of treatment. Cariprazine is FDA approved for the acute treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adults. Post hoc analyses of pooled data from 3 pivotal trials of cariprazine in manic/mixed episodes associated with bipolar I disorder were conducted to investigate the effect of cariprazine on various criteria of response and remission. METHODS: The constituent studies were 3-week randomized, double-blind, placebo-controlled, multicenter, parallel-group phase II/III studies in adult patients (age 18-65 years) with bipolar I disorder (NCT00488618, NCT01058096, NCT01058668). Post hoc analyses included Young Mania Rating Scale (YMRS) outcomes for response (≥50% decrease in score), remission (total score ≤12 and ≤8), cumulative remission, and global improvement. Additionally, composite remission (YMRS total score ≤12 plus Montgomery-Åsberg Depression Rating Scale total score ≤12) and worsening/switch to depression (MADRS total score ≥15) by week were investigated. RESULTS:Rates of response and remission were significantly greater for cariprazine versus placebo on every measure evaluated (P < .01 all analyses); the estimated number needed to treat for each measure was ≤10. There was no evidence of worsening/switch to depression. LIMITATIONS: Post hoc analyses, short treatment duration, no active comparator. DISCUSSION: Cariprazine-treated patients with bipolar I disorder attained clinically significant improvement in manic symptoms as shown by significantly greater rates of response and remission versus placebo; improvement in manic symptoms did not induce depressive symptoms.
RCT Entities:
BACKGROUND: Rates of response and remission are measures that endorse the clinical significance of treatment. Cariprazine is FDA approved for the acute treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adults. Post hoc analyses of pooled data from 3 pivotal trials of cariprazine in manic/mixed episodes associated with bipolar I disorder were conducted to investigate the effect of cariprazine on various criteria of response and remission. METHODS: The constituent studies were 3-week randomized, double-blind, placebo-controlled, multicenter, parallel-group phase II/III studies in adult patients (age 18-65 years) with bipolar I disorder (NCT00488618, NCT01058096, NCT01058668). Post hoc analyses included Young Mania Rating Scale (YMRS) outcomes for response (≥50% decrease in score), remission (total score ≤12 and ≤8), cumulative remission, and global improvement. Additionally, composite remission (YMRS total score ≤12 plus Montgomery-Åsberg Depression Rating Scale total score ≤12) and worsening/switch to depression (MADRS total score ≥15) by week were investigated. RESULTS: Rates of response and remission were significantly greater for cariprazine versus placebo on every measure evaluated (P < .01 all analyses); the estimated number needed to treat for each measure was ≤10. There was no evidence of worsening/switch to depression. LIMITATIONS: Post hoc analyses, short treatment duration, no active comparator. DISCUSSION: Cariprazine-treated patients with bipolar I disorder attained clinically significant improvement in manic symptoms as shown by significantly greater rates of response and remission versus placebo; improvement in manic symptoms did not induce depressive symptoms.
Authors: Roberto Palacios-Garrán; Vicent Llorca-Bofí; Gara Arteaga-Henriquez; Enrique Del Agua Journal: Front Psychiatry Date: 2022-05-11 Impact factor: 5.435
Authors: Amber Edinoff; Miriam T Ruoff; Yahya T Ghaffar; Arthur Rezayev; Devanshi Jani; Adam M Kaye; Elyse M Cornett; Alan D Kaye; Omar Viswanath; Ivan Urits Journal: Psychopharmacol Bull Date: 2020-09-14
Authors: Tijana Sagorac Gruichich; Juan Camilo David Gomez; Gabriel Zayas-Cabán; Melvin G McInnis; Amy L Cochran Journal: Bipolar Disord Date: 2021-02-26 Impact factor: 6.744
Authors: Suresh Durgam; Willie Earley; Kaifeng Lu; György Németh; István Laszlovszky; Stephen Volk; Robert E Litman Journal: Int J Clin Pract Date: 2017-11-09 Impact factor: 2.503